Importance: Cerebral venous sinus thrombosis (CVST) with thrombocytopenia, a rare and serious condition, has been described in Europe following receipt of the ChAdOx1 nCoV-19 vaccine (Oxford/AstraZeneca), which uses a chimpanzee adenoviral vector. A mechanism similar to autoimmune heparin-induced thrombocytopenia (HIT) has been proposed. In the US, the Ad26.COV2.S COVID-19 vaccine (Janssen/Johnson & Johnson), which uses a human adenoviral vector, received Emergency Use Authorization (EUA) on February 27, 2021. By April 12, 2021, approximately 7 million Ad26.COV2.S vaccine doses had been given in the US, and 6 cases of CVST with thrombocytopenia had been identified among the recipients, resulting in a temporary national pause in vaccination with this product on April 13, 2021. Objective: To describe reports of CVST with thrombocytopenia following Ad26.COV2.S vaccine receipt. Design, Setting, and Participants: Case series of 12 US patients with CVST and thrombocytopenia following use of Ad26.COV2.S vaccine under EUA reported to the Vaccine Adverse Event Reporting System (VAERS) from March 2 to April 21, 2021 (with follow-up reported through April 21, 2021). Exposures: Receipt of Ad26.COV2.S vaccine. Main Outcomes and Measures: Clinical course, imaging, laboratory tests, and outcomes after CVST diagnosis obtained from VAERS reports, medical record review, and discussion with clinicians. Results: Patients' ages ranged from 18 to younger than 60 years; all were White women, reported from 11 states. Seven patients had at least 1 CVST risk factor, including obesity (n = 6), hypothyroidism (n = 1), and oral contraceptive use (n = 1); none had documented prior heparin exposure. Time from Ad26.COV2.S vaccination to symptom onset ranged from 6 to 15 days. Eleven patients initially presented with headache; 1 patient initially presented with back pain and later developed headache. Of the 12 patients with CVST, 7 also had intracerebral hemorrhage; 8 had non-CVST thromboses. After diagnosis of CVST, 6 patients initially received heparin treatment. Platelet nadir ranged from 9 ×103/µL to 127 ×103/µL. All 11 patients tested for the heparin-platelet factor 4 HIT antibody by enzyme-linked immunosorbent assay (ELISA) screening had positive results. All patients were hospitalized (10 in an intensive care unit [ICU]). As of April 21, 2021, outcomes were death (n = 3), continued ICU care (n = 3), continued non-ICU hospitalization (n = 2), and discharged home (n = 4). Conclusions and Relevance: The initial 12 US cases of CVST with thrombocytopenia after Ad26.COV2.S vaccination represent serious events. This case series may inform clinical guidance as Ad26.COV2.S vaccination resumes in the US as well as investigations into the potential relationship between Ad26.COV2.S vaccine and CVST with thrombocytopenia.
Importance: Cerebral venous sinus thrombosis (CVST) with thrombocytopenia, a rare and serious condition, has been described in Europe following receipt of the ChAdOx1 nCoV-19 vaccine (Oxford/AstraZeneca), which uses a chimpanzee adenoviral vector. A mechanism similar to autoimmune heparin-induced thrombocytopenia (HIT) has been proposed. In the US, the Ad26.COV2.S COVID-19 vaccine (Janssen/Johnson & Johnson), which uses a human adenoviral vector, received Emergency Use Authorization (EUA) on February 27, 2021. By April 12, 2021, approximately 7 million Ad26.COV2.S vaccine doses had been given in the US, and 6 cases of CVST with thrombocytopenia had been identified among the recipients, resulting in a temporary national pause in vaccination with this product on April 13, 2021. Objective: To describe reports of CVST with thrombocytopenia following Ad26.COV2.S vaccine receipt. Design, Setting, and Participants: Case series of 12 US patients with CVST and thrombocytopenia following use of Ad26.COV2.S vaccine under EUA reported to the Vaccine Adverse Event Reporting System (VAERS) from March 2 to April 21, 2021 (with follow-up reported through April 21, 2021). Exposures: Receipt of Ad26.COV2.S vaccine. Main Outcomes and Measures: Clinical course, imaging, laboratory tests, and outcomes after CVST diagnosis obtained from VAERS reports, medical record review, and discussion with clinicians. Results:Patients' ages ranged from 18 to younger than 60 years; all were White women, reported from 11 states. Seven patients had at least 1 CVST risk factor, including obesity (n = 6), hypothyroidism (n = 1), and oral contraceptive use (n = 1); none had documented prior heparin exposure. Time from Ad26.COV2.S vaccination to symptom onset ranged from 6 to 15 days. Eleven patients initially presented with headache; 1 patient initially presented with back pain and later developed headache. Of the 12 patients with CVST, 7 also had intracerebral hemorrhage; 8 had non-CVST thromboses. After diagnosis of CVST, 6 patients initially received heparin treatment. Platelet nadir ranged from 9 ×103/µL to 127 ×103/µL. All 11 patients tested for the heparin-platelet factor 4 HIT antibody by enzyme-linked immunosorbent assay (ELISA) screening had positive results. All patients were hospitalized (10 in an intensive care unit [ICU]). As of April 21, 2021, outcomes were death (n = 3), continued ICU care (n = 3), continued non-ICU hospitalization (n = 2), and discharged home (n = 4). Conclusions and Relevance: The initial 12 US cases of CVST with thrombocytopenia after Ad26.COV2.S vaccination represent serious events. This case series may inform clinical guidance as Ad26.COV2.S vaccination resumes in the US as well as investigations into the potential relationship between Ad26.COV2.S vaccine and CVST with thrombocytopenia.
Authors: Gustavo Saposnik; Fernando Barinagarrementeria; Robert D Brown; Cheryl D Bushnell; Brett Cucchiara; Mary Cushman; Gabrielle deVeber; Jose M Ferro; Fong Y Tsai Journal: Stroke Date: 2011-02-03 Impact factor: 7.914
Authors: Jessica R MacNeil; John R Su; Karen R Broder; Alice Y Guh; Julia W Gargano; Megan Wallace; Stephen C Hadler; Heather M Scobie; Amy E Blain; Danielle Moulia; Matthew F Daley; Veronica V McNally; José R Romero; H Keipp Talbot; Grace M Lee; Beth P Bell; Sara E Oliver Journal: MMWR Morb Mortal Wkly Rep Date: 2021-04-30 Impact factor: 17.586
Authors: Maheshi N Ramasamy; Angela M Minassian; Katie J Ewer; Amy L Flaxman; Pedro M Folegatti; Daniel R Owens; Merryn Voysey; Parvinder K Aley; Brian Angus; Gavin Babbage; Sandra Belij-Rammerstorfer; Lisa Berry; Sagida Bibi; Mustapha Bittaye; Katrina Cathie; Harry Chappell; Sue Charlton; Paola Cicconi; Elizabeth A Clutterbuck; Rachel Colin-Jones; Christina Dold; Katherine R W Emary; Sofiya Fedosyuk; Michelle Fuskova; Diane Gbesemete; Catherine Green; Bassam Hallis; Mimi M Hou; Daniel Jenkin; Carina C D Joe; Elizabeth J Kelly; Simon Kerridge; Alison M Lawrie; Alice Lelliott; May N Lwin; Rebecca Makinson; Natalie G Marchevsky; Yama Mujadidi; Alasdair P S Munro; Mihaela Pacurar; Emma Plested; Jade Rand; Thomas Rawlinson; Sarah Rhead; Hannah Robinson; Adam J Ritchie; Amy L Ross-Russell; Stephen Saich; Nisha Singh; Catherine C Smith; Matthew D Snape; Rinn Song; Richard Tarrant; Yrene Themistocleous; Kelly M Thomas; Tonya L Villafana; Sarah C Warren; Marion E E Watson; Alexander D Douglas; Adrian V S Hill; Teresa Lambe; Sarah C Gilbert; Saul N Faust; Andrew J Pollard Journal: Lancet Date: 2020-11-19 Impact factor: 79.321
Authors: Sebastian D Romano; Anna J Blackstock; Ethel V Taylor; Suad El Burai Felix; Stacey Adjei; Christa-Marie Singleton; Jennifer Fuld; Beau B Bruce; Tegan K Boehmer Journal: MMWR Morb Mortal Wkly Rep Date: 2021-04-16 Impact factor: 17.586
Authors: David K Shay; Julianne Gee; John R Su; Tanya R Myers; Paige Marquez; Ruiling Liu; Bicheng Zhang; Charles Licata; Thomas A Clark; Tom T Shimabukuro Journal: MMWR Morb Mortal Wkly Rep Date: 2021-05-07 Impact factor: 35.301
Authors: Jonathan Douxfils; Julien Favresse; Jean-Michel Dogné; Thomas Lecompte; Sophie Susen; Charlotte Cordonnier; Aurélien Lebreton; Robert Gosselin; Pierre Sié; Gilles Pernod; Yves Gruel; Philippe Nguyen; Caroline Vayne; François Mullier Journal: Thromb Res Date: 2021-05-15 Impact factor: 3.944
Authors: Mayte Sánchez van Kammen; Mirjam R Heldner; Justine Brodard; Adrian Scutelnic; Suzanne Silvis; Verena Schroeder; Johanna A Kremer Hovinga; Saskia Middeldorp; Marcel Levi; Sini Hiltunen; Erik Lindgren; Maryam Mansour; Antonio Arauz; Miguel A Barboza; Susanna M Zuurbier; Diana Aguiar de Sousa; Jose M Ferro; Urs Fischer; Thalia S Field; Katarina Jood; Turgut Tatlisumak; Jukka Putaala; Marcel Arnold; Jonathan M Coutinho Journal: JAMA Date: 2021-07-27 Impact factor: 56.272